In the ER negative subgroup of BC in women receiving chemotherapy and HER2 targeted therapy the difference was less marked (pCR rate of 53% for IHC 3+ versus 38% for IHC 2+/gene amplified, respectively). Here, ERBB2 is linked to breast cancer.